Lilly/Amylin Look To Limit Byetta Access Due To Cartridge Shortage
This article was originally published in The Pink Sheet Daily
Executive Summary
Exenatide supplies for patients already on the therapy will be maintained, Lilly said.
You may also be interested in...
Byetta Shortage Is Bygone Era
After backfilling the supply channel using contract manufacturers, Lilly/Amylin resume promotions for the injectable type 2 diabetes product.
Byetta Shortage Is Bygone Era
After backfilling the supply channel using contract manufacturers, Lilly/Amylin resume promotions for the injectable type 2 diabetes product.
Nastech/Amylin’s Exenatide Nasal Spray Deal Could Be Shot In The Arm For Lilly
Lilly, which markets injectable exenatide, may inherit commercialization rights to the nasal spray formulation if Nastech/Amylin’s development proves successful.